John Thomas Sells 10,000 Shares of Genelux (NASDAQ:GNLX) Stock

Genelux Corporation (NASDAQ:GNLX) Director John Thomas sold 10,000 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $2.98, for a total value of $29,800.00. Following the sale, the director owned 472,784 shares in the company, valued at $1,408,896.32. The trade was a 2.07% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Genelux Stock Performance

Shares of GNLX stock opened at $3.00 on Thursday. Genelux Corporation has a fifty-two week low of $2.29 and a fifty-two week high of $8.53. The firm has a market capitalization of $134.52 million, a price-to-earnings ratio of -3.53 and a beta of 0.56. The stock’s 50-day simple moving average is $2.75 and its 200-day simple moving average is $3.22.

Genelux (NASDAQ:GNLX) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.02). As a group, equities analysts forecast that Genelux Corporation will post -0.8 earnings per share for the current year.

Institutional Investors Weigh In On Genelux

A number of large investors have recently bought and sold shares of the company. Creative Planning lifted its holdings in Genelux by 4.7% in the third quarter. Creative Planning now owns 46,108 shares of the company’s stock valued at $194,000 after acquiring an additional 2,084 shares during the period. Raymond James Financial Inc. lifted its holdings in Genelux by 22.6% in the second quarter. Raymond James Financial Inc. now owns 28,933 shares of the company’s stock valued at $83,000 after acquiring an additional 5,333 shares during the period. Geode Capital Management LLC lifted its holdings in Genelux by 1.8% in the second quarter. Geode Capital Management LLC now owns 318,825 shares of the company’s stock valued at $915,000 after acquiring an additional 5,596 shares during the period. Jefferies Financial Group Inc. acquired a new position in Genelux in the fourth quarter valued at approximately $48,000. Finally, Squarepoint Ops LLC acquired a new position in Genelux in the fourth quarter valued at approximately $52,000. Hedge funds and other institutional investors own 37.33% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on GNLX shares. Wall Street Zen lowered Genelux from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Benchmark dropped their target price on Genelux from $23.00 to $20.00 and set a “speculative buy” rating on the stock in a research report on Friday, March 20th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Genelux in a research report on Tuesday, April 21st. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.00.

About Genelux

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.

Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.